Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy
Shares of Adaptimmune Therapeutics plc ADAP rose about 8% after the company announced that the FDA has granted Orphan Drug Designation (ODD) to SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Notably, the Orphan Drug designation is granted to drugs capable of treating rare diseases that affect less than 200,000 people in the United States. This designation also makes the company entitled to certain other benefits, including tax credits related to clinical trial expenses and an exemption from the FDA user fee.
Shares of the company have plunged 70.4% year to date compared with the industry’s decline of 2.7%.
Adaptimmune’s ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigens expressed in a number of solid tumor cell types. The MAGE-A4 antigen is among the most commonly expressed cancer testis antigens.
Adaptimmune is currently investigating its ADP-A2M4 SPEAR T-cells in two types of sarcoma: synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). The company is conducting three studies for the same.
In July 2019, the company initiated phase II SPEARHEAD-1 study with ADP-A2M4 SPEAR T-cells to treat patients with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS), with the aim to launch ADP-A2M4 in 2022. This apart, the company is conducting a low–dose radiation sub-study to enhance antitumor activity and a pilot study is also underway for ADP-A2M4. Both radiation sub-study and pilot study include sarcoma as well as multiple other solid tumor indications.
Adaptimmune is also evaluating a next-generation SPEAR T-cell (ADP-A2M4CD8) in sarcoma as well as other solid tumor indications in the SURPASS study.
Zacks Rank & Stocks to Consider
Currently, Adaptimmune is a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the biotech sector are Amgen Inc. AMGN, Acorda Therapeutics Inc. ACOR and Celcuity Inc. CELC All of these carry a Zacks Rank #1 (Strong Buy), at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Amgen’s earnings per share estimates have increased from $13.90 to $14.30 for 2019 and from $14.78 to $15.42 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, the average beat being 6.72%.
Acorda’s loss per share estimates for the current year narrowed from $3.59 to $2.74 in the past 60 days. The company delivered a positive earnings surprise in the last four quarters, the average beat being 69.68%.
Celcuity’s loss per share estimates narrowed from 81 cents to 70 cents for 2019 and from 96 cents to 71 cents for 2020 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, the average beat being 25.76%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click to get this free report
Amgen Inc. (AMGN): Free Stock Analysis Report
Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report
Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report
Celcuity, Inc. (CELC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.